TELO — Telomir Pharmaceuticals Balance Sheet
0.000.00%
- $111.04m
- $107.76m
Annual balance sheet for Telomir Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Cash | |||
Cash and Short Term Investments | 0 | 0.001 | 0.001 |
Net Total Receivables | — | — | 0.13 |
Prepaid Expenses | |||
Total Other Current Assets | |||
Total Current Assets | 0 | 0.049 | 0.435 |
Other Long Term Assets | |||
Total Assets | 0 | 0.049 | 4.77 |
Payable / Accrued | |||
Notes Payable / Short Term Debt | |||
Total Other Current Liabilities | |||
Total Current Liabilities | 0.138 | 0.986 | 1.34 |
Total Long Term Debt | |||
Total Debt | |||
Total Liabilities | 0.138 | 0.986 | 1.34 |
Common Stock | |||
Additional Paid In Capital | |||
Retained Earnings (Accumulated Deficit) | |||
Other Equity | |||
Total Equity | -0.138 | -0.937 | 3.44 |
Total Liabilities & Shareholders' Equity | 0 | 0.049 | 4.77 |
Total Common Shares Outstanding |